689 results on '"Kiyota, Naomi"'
Search Results
2. The european organisation for research and treatment of cancer head and neck cancer module (EORTC QLQ-HN43): Estimates for minimal important difference and minimal important change
3. Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008
4. Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial
5. Novel approach of prophylactic radiation to reduce toxicities comparing 2-step40 with 56-Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck, an intergroup phase III trial (JCOG1912, NEW BRIDGE)
6. Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database
7. Summary of Japanese clinical practice guidelines for head and neck cancer - 2022 update edited by the Japan society for head and neck cancer
8. Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF-CRT) for locally advanced squamous cell carcinoma of the external auditory canal
9. Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)
10. Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial
11. Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale
12. Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer
13. Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck.
14. Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II/III trial of JCOG1008.
15. Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer.
16. Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody
17. Analysis of B‐cell receptor repertoire to evaluate immunogenicity of monovalent Omicron XBB.1.5 mRNA vaccines
18. Statistical Analysis Methods and Reporting of Patient-Reported Outcomes in Randomized Controlled Trials for Cancer Conducted in Japan: A Systematic Review
19. Targeting Anterior Commissure Involvement with Hyperfractionated Radiotherapy for T1–T2 Squamous Cell Carcinoma of the Glottic Larynx
20. Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome (ePRO) monitoring in patients with unresectable advanced cancers or metastatic/recurrent solid tumors
21. Correction to: Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan
22. Incidence of venous thromboembolism in patients with solid cancers in Japan: retrospective study of 2735 patients
23. Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance
24. Current status and future perspective of postoperative treatment for locally advanced squamous cell carcinoma of the head and neck.
25. Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial)
26. The impact of electronic versus paper-based data capture on data collection logistics and on missing scores in thyroid cancer patients
27. Risk factors for osteoradionecrosis of the jaw in patients with head and neck squamous cell carcinoma
28. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan
29. Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial
30. Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age
31. Long‐term health‐related quality of life in head and neck cancer survivors: A large multinational study.
32. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan.
33. Extent of thyroidectomy and paratracheal lymph node dissection in total pharyngolaryngectomy for pyriform sinus cancer, and recurrence, survival, and postoperative hypoparathyroidism: A multicenter retrospective study
34. MO28-6 Feasibility of the online-based QOL survey in patients with head and neck cancer. A multi-center, prospective study
35. Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy
36. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
37. Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis
38. Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin
39. Role of intensive nutrition support and prophylactic percutaneous endoscopic gastrostomy during concomitant chemoradiotherapy for oropharyngeal cancer
40. 18: Secondary analysis of JCOG1008: Frequency and risk factors associated with the hypothyroidism
41. Expression of preference for the disclosure of secondary findings of comprehensive genomic profiling tests by cancer patients and relatives
42. Oncological outcomes of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5‐fluorouracil for locally advanced squamous cell carcinoma of the external auditory canal: A single‐center study
43. Summary of Japanese clinical practice guidelines for head and neck cancer - 2022 update edited by the Japan society for head and neck cancer
44. A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer.
45. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141
46. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid
47. Ibuprofen gargle for chemo- or Chemoradiotherapy-induced Oral Mucositis: a feasibility study
48. Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus
49. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
50. Weekly versus 3‐weekly cisplatin along with radiotherapy for locoregionally advanced non‐nasopharyngeal head and neck cancers: Is the equipoise in literature addressed yet?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.